REGENXBIO
RGNXRGNX · Stock Price
Historical price data
Overview
REGENXBIO is a clinical-stage biotech with a mission to deliver life-changing gene therapies through its foundational NAV Technology Platform. Its achievements include enabling the blockbuster therapy ZOLGENSMA® and building a diverse internal pipeline, most notably in MPS II and Duchenne muscular dystrophy. The company's strategy combines internal development of wholly-owned assets with a high-margin, capital-efficient licensing model that provides recurring revenue and validates its technology.
Technology Platform
The proprietary NAV Technology Platform is a portfolio of over 100 adeno-associated virus (AAV) vectors, including AAV7, AAV8, AAV9, and AAVrh10, designed for targeted delivery of therapeutic genes with enhanced tropism, reduced pre-existing immunity, and scalable manufacturability.
Pipeline
2| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Aflibercept (2.0 mg) | Diabetic Macular Edema | Phase 2 | |
| Single intravenous (IV) dose of human Low Density Lipoprotei... | Homozygous Familial Hypercholesterolemia (HoFH) | Pre-clinical |
Opportunities
Risk Factors
Competitive Landscape
REGENXBIO faces intense competition in its therapeutic areas from both established drugs and other gene therapy developers. Its unique advantage lies in its dual role as a developer and an enabler, with a validated platform generating royalties and a capital-efficient strategy bolstered by partnership revenue.
